Efficacy of Maternal Influenza Vaccination Against All-Cause Lower Respiratory Tract Infection Hospitalizations in Young Infants: Results From a Randomized Controlled Trial

Marta C Nunes, Clare L Cutland, Stephanie Jones, Sarah Downs, Adriana Weinberg, Justin R Ortiz, Kathleen M Neuzil, Eric A F Simões, Keith P Klugman, Shabir A Madhi, Marta C Nunes, Clare L Cutland, Stephanie Jones, Sarah Downs, Adriana Weinberg, Justin R Ortiz, Kathleen M Neuzil, Eric A F Simões, Keith P Klugman, Shabir A Madhi

Abstract

Background: Influenza immunization of pregnant women protects their young infants against laboratory-confirmed influenza infection. Influenza infection might predispose to subsequent bacterial infections that cause severe pneumonia. In a secondary analysis of a randomized clinical trial (RCT), we evaluated the effect of maternal vaccination on infant hospitalizations for all-cause acute lower respiratory tract infection (ALRI).

Methods: Infants born to women who participated in a double-blind placebo-controlled RCT in 2011 and 2012 on the efficacy of trivalent inactivated influenza vaccine (IIV) during pregnancy were followed during the first 6 months of life.

Results: The study included 1026 infants born to IIV recipients and 1023 born to placebo recipients. There were 52 ALRI hospitalizations (median age, 72 days). The incidence (per 1000 infant-months) of ALRI hospitalizations was lower in infants born to IIV recipients (3.4 [95% confidence interval {CI}, 2.2-5.4]; 19 cases) compared with placebo recipients (6.0 [95% CI, 4.3-8.5]; 33 cases) with a vaccine efficacy of 43.1% (P = .050). Thirty of the ALRI hospitalizations occurred during the first 90 days of life, 9 in the IIV group (3.0 [95% CI, 1.6-5.9]) and 21 in the placebo group (7.2 [95% CI, 4.7-11.0]) (incidence rate ratio, 0.43 [95% CI, .19-.93]) for a vaccine efficacy of 57.5% (P = .032). The incidence of ALRI hospitalizations was similar in the IIV and placebo group for infants >3 months of age. Forty-four of the hospitalized infants were tested for influenza virus infection and 1 tested positive.

Conclusions: Using an RCT as a vaccine probe, influenza vaccination during pregnancy decreased all-cause ALRI hospitalization during the first 3 months of life, suggesting possible protection against subsequent bacterial infections that influenza infection might predispose to.

Clinical trial registration: NCT01306669.

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival curve showing cumulative proportion of infants without lower respiratory infection–associated hospitalizations during the follow-up period by study group. P values calculated by log-rank test. Abbreviation: IIV, inactivated influenza vaccine.

References

    1. Liu L, Oza S, Hogan D et al. . Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet 2016; 388:3027–35.
    1. Nair H, Simões EA, Rudan I et al. ; Severe Acute Lower Respiratory Infections Working Group Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 2013; 381:1380–90.
    1. Weinberger DM, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis 2012; 205:458–65.
    1. Shrestha S, Foxman B, Berus J et al. . The role of influenza in the epidemiology of pneumonia. Sci Rep 2015; 5:15314.
    1. Jain S, Williams DJ, Arnold SR et al. ; CDC EPIC Study Team Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372:835–45.
    1. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000; 342:225–31.
    1. Grijalva CG, et al. The role of influenza and parainfluenza infections in nasopharyngeal pneumococcal acquisition among young children. Clin Infect Dis 2014; 58:1369–76.
    1. Gray BM, Converse GM 3rd, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980; 142:923–33.
    1. Zaman K, Roy E, Arifeen SE et al. . Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359:1555–64.
    1. Madhi SA, Cutland CL, Kuwanda L et al. ; Maternal Flu Trial (Matflu) Team Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014; 371:918–31.
    1. Tapia MD, Sow SO, Tamboura B et al. . Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis 2016; 16:1026–35.
    1. Nunes MC, Cutland CL, Jones S et al. ; Maternal Flu Trial Team Duration of infant protection against influenza illness conferred by maternal immunization: secondary analysis of a randomized clinical trial. JAMA Pediatr 2016; 170:840–7.
    1. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vázquez M. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis 2010; 51:1355–61.
    1. Black SB, Shinefield HR, France EK, Fireman BH, Platt ST, Shay D; Vaccine Safety Datalink Workgroup Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. Am J Perinatol 2004; 21:333–9.
    1. Dabrera G, Zhao H, Andrews N et al. . Effectiveness of seasonal influenza vaccination during pregnancy in preventing influenza infection in infants, England, 2013/14. Euro Surveill 2014; 19:20959.
    1. Eick AA, Uyeki TM, Klimov A et al. . Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med 2011; 165:104–11.
    1. France EK, Smith-Ray R, McClure D et al. . Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. Arch Pediatr Adolesc Med 2006; 160:1277–83.
    1. Poehling KA, Szilagyi PG, Staat MA et al. ; New Vaccine Surveillance Network Impact of maternal immunization on influenza hospitalizations in infants. Am J Obstet Gynecol 2011; 204:S141–8.
    1. Regan AK, de Klerk N, Moore HC, Omer SB, Shellam G, Effler PV. Effect of maternal influenza vaccination on hospitalization for respiratory infections in newborns: a retrospective cohort study. Pediatr Infect Dis J 2016; 35:1097–103.
    1. World Health Organization. Recommended viruses for influenza vaccines for use in the 2011 Southern Hemisphere influenza season. Geneva, Switzerland: WHO, 2010. Available at: . Accessed 7 June 2016.
    1. VAXIGRIP. Inactivated influenza vaccine (split virion) product information. Lyon, France: Sanofi Pasteur, 2011. Available at: . Accessed 7 June 2016.
    1. National Institute for Communicable Diseases, National Health Laboratory Service Influenza surveillance report—South Africa. Available at: . Accessed 7 June 2016.
    1. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002; 186:341–50.
    1. Nunes MC, Kuschner Z, Rabede Z et al. . Polyomaviruses-associated respiratory infections in HIV-infected and HIV-uninfected children. J Clin Virol 2014; 61:571–8.
    1. Madhi SA, Klugman KP; Vaccine Trialist Group A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10:811–3.
    1. Madhi SA, Ludewick H, Kuwanda L et al. . Pneumococcal coinfection with human metapneumovirus. J Infect Dis 2006; 193:1236–43.
    1. Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005; 40:1511–8.
    1. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962–70.
    1. Mina MJ, Klugman KP. The role of influenza in the severity and transmission of respiratory bacterial disease. Lancet Respir Med 2014; 2:750–63.
    1. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008; 14:558–64.
    1. Lee LN, Dias P, Han D et al. . A mouse model of lethal synergism between influenza virus and Haemophilus influenzae. Am J Pathol 2010; 176:800–11.
    1. Iverson AR, Boyd KL, McAuley JL, Plano LR, Hart ME, McCullers JA. Influenza virus primes mice for pneumonia from Staphylococcus aureus. J Infect Dis 2011; 203:880–8.
    1. Wolter N, Tempia S, Cohen C et al. . High nasopharyngeal pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal pneumonia. J Infect Dis 2014; 210:1649–57.
    1. Rudan I, O’Brien KL, Nair H et al. ; Child Health Epidemiology Reference Group (CHERG) Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health 2013; 3:010401.
    1. Feikin DR, Scott JA, Gessner BD. Use of vaccines as probes to define disease burden. Lancet 2014; 383:1762–70.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться